Th17 cytokines in inflammatory bowel diseases: Discerning the good from the bad

International Reviews of Immunology

Volumn 32, Issue 5-6, 2013, Pages 526-533

  Troncone, Edoardo ^a   Marafini, Irene ^a   Pallone, Francesco ^a   Monteleone, Giovanni ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Crohn's disease; IL 17; IL 21; IL 23; Ulcerative colitis

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHEMOKINE RECEPTOR CX3CR1; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 26; INTERLEUKIN 6; LYMPHOCYTE ANTIGEN RECEPTOR; RETINOID RELATED ORPHAN RECEPTOR ALPHA; RETINOID RELATED ORPHAN RECEPTOR GAMMA; SECUKINUMAB; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB;

ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; CROHN DISEASE; CYTOKINE PRODUCTION; ENTERITIS; HUMAN; INTESTINE EPITHELIUM CELL; LAMINA PROPRIA; LYMPHOCYTE DIFFERENTIATION; MESENTERY LYMPH NODE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; ULCERATIVE COLITIS;

ANIMALS; CROHN DISEASE; CYTOKINES; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATORY BOWEL DISEASES; MICE; TH17 CELLS;

EID: 84887328950     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2013.823421     Document Type: Article

References (70)

1. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel diseases. Annu Rev Immunol 2010;28:573-621.
2. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease.Nature 2011;474(7351):298-306.
3. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007;117(3):514-521.
4. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996;157(3):1261-1270.
5. Monteleone G, Biancone L, Marasco R, et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997;112(4): 1169-1178.
6. Monteleone G, MacDonald TT. Manipulation of cytokines in the management of patients with inflammatory bowel disease. AnnMed 2000;32(8):552-560.
7. Reinisch W, Hommes DW, Van Assche G, et al. A dose escalating, placebo controlled, double blind, single dose andmultidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients withmoderate to severe Crohn's disease. Gut 2006;55(8):1138-1144.
8. Hommes DW, Mikhajlova TL, Stoinov S, et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006;55(8):1131-1137.
9. Reinisch W, de Villiers W, Bene L, et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 2010;16(2):233-242.
10. Korn T, Bettelli E,Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009;27:485-517.
11. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature 2008;453(7198):1051-1057.
12. Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009;139(3):485-498.
13. Salzman NH, Hung K, Haribhai D, et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 2010;11(1):76-83.
14. Atarashi K, Nishimura J, Shima T, et al. ATP drives lamina propria T(H)17 cell differentiation. Nature 2008;455(7214):808-812.
15. Hall JA, Bouladoux N, Sun CM, et al. Commensal DNA limits regulatory T cell conversion and is a natural adjuvant of intestinal immune responses. Immunity 2008;29(4):637-649.
16. Hirota K, Turner JE, Villa M, et al. Plasticity of TH17 cells in Peyer's patches is responsible for the induction of T cell-dependent IgA responses. Nat Immunol 2013;14(4):372-379.
17. Ivanov II,McKenzie BS, Zhou L.Theorphan nuclear receptor RORgammat directs the differentiation programof proinflammatory IL-17+ T helper cells. Cell 2006;126(6):1121-1133.
18. Yang XO, Pappu BP, Nurieva R, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008;28(1):29-39.
19. Ciofani M, Madar A, Galan C, et al. A validated regulatory network for Th17 cell specification. Cell 2012;151(2):289-303.
20. Zhang F, Meng G, Strober W. Interactions among the transcription factors Runx1, RORgammat and Foxp3 regulate the differentiation of interleukin 17-producing T cells. Nat Immunol 2008;9(11): 1297-1306.
21. Sato K,Miyoshi F, Yokota K, et al.Marked induction of c-Maf protein duringTh17 cell differentiation and its implication inmemoryThcell development. J Biol Chem 2011;286(17):14963-14971.
22. Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007;8(9):967-974.
23. Maggi L, Santarlasci V, CaponeM, et al. CD161 is amarker of all human IL-17-producing T-cell subsets and is induced by RORC. Eur J Immunol 2010;40(8):2174-2181.
24. Martin B,Hirota K, Cua DJ, et al. Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity 2009;31(2):321-330.
25. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003;52(1):65-70.
26. Spits H, Di Santo JP.The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol 2011;12(1):21-27.
27. Seiderer J, Elben I,Diegelmann J, et al. Role of the novelTh17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis 2008;14(4):437-445.
28. Brand S, Beigel F, Olszak T, et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 2006;290(4):G827-G838.
29. Dambacher J, Beigel F, Zitzmann K, et al.The role of the novelTh17 cytokine IL-26 in intestinal inflammation. Gut 2009;58(9):1207-1217.
30. Kleinschek MA, Boniface K, Sadekova S, et al. Circulating and gut-resident humanTh17 cells express CD161 and promote intestinal inflammation. J ExpMed 2009;206(3):525-534.
31. Hovhannisyan Z, Treatman J, Littman DR, Mayer L. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology 2011;140(3):957-965.
32. Boniface K, Blumenschein WM, Brovont-Porth K, et al. HumanTh17 cells comprise heterogeneous subsets including IFN-gamma-producing cells with distinct properties from the Th1 lineage. J Immunol 2010;185(1):679-687.
33. Volpe E, Servant N, Zollinger R, et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 2008;9(6):650-657.
34. Lee YK, Turner H,Maynard CL, et al. Late developmental plasticity in the T helper 17 lineage. Immunity 2009;30(1):92-107.
35. Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001;108(4):601-609.
36. Zorzi F,Monteleone I, Sarra M, et al. Distinct profiles of effector cytokinesmark the different phases of Crohn's disease. PLoS One 2013;8(1):e54562.
37. Nurieva R, Yang XO, Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007;448(7152):480-483.
38. Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007;448(7152):484-487.
39. Fina D, Sarra M, Fantini MC, et al. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 2008;134(4):1038-1048.
40. Sarra M, Monteleone I, Stolfi C, et al. Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm Bowel Dis 2010;16(8):1332-1339.
41. Monteleone G,Monteleone I, Fina D, et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology. 2005;128(3):687-694.
42. Jovanovic DV, Di Battista JA, Martel-Pelletier J, et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 1998;160(7):3513-3521.
43. Ye P, Rodriguez FH, Kanaly S, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J ExpMed 2001;194(4):519-527.
44. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6(11):1133-1141.
45. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002;20:495-549.
46. Ogawa A, Andoh A, Araki Y, et al.Neutralization of interleukin-17 aggravates dextran sulfate sodiuminduced colitis in mice. Clin Immunol 2004;110(1):55-62.
47. Yang XO, Chang SH, Park H, et al. Regulation of inflammatory responses by IL-17F. J Exp Med 2008;205(5):1063-1075.
48. Kinugasa T, Sakaguchi T, Gu X, Reinecker HC. Claudins regulate the intestinal barrier in response to immune mediators. Gastroenterology 2000;118(6):1001-1011.
49. Medina-Contreras O, Geem D, Laur O, et al. CX3CR1 regulates intestinal macrophage homeostasis, bacterial translocation, and colitogenic Th17 responses in mice. J Clin Invest 2011;121(12): 4787-4795.
50. Zhang Z, Zheng M, Bindas J, et al. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis 2006;12(5):382-388.
51. Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003;14(2):155-174.
52. Chaudhry A, Rudra D, Treuting P, et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependentmanner. Science 2009;326(5955):986-991.
53. Elson CO, Cong Y,Weaver CT, et al.Monoclonal anti-interleukin 23 reverses active colitis in a T cellmediated model inmice. Gastroenterology 2007;132(7):2359-2370.
54. Leppkes M, Becker C, Ivanov II, et al. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 2009;136(1): 257-267.
55. Noguchi D, Wakita D, Tajima M, et al. Blocking of IL-6 signaling pathway prevents CD4+ T cellmediated colitis in a T(h)17-independentmanner. Int Immunol 2007;19(12):1431-1440.
56. O'Connor W Jr, Kamanaka M, Booth CJ, et al. A protective function for interleukin 17A in T cellmediated intestinal inflammation. Nat Immunol 2009;10(6):603-609.
57. Pan HF, Li XP, Zheng SG, Ye DQ. Emerging role of interleukin-22 in autoimmune diseases. Cytokine Growth Factor Rev 2013;24(1):51-57
58. Monteleone I, MacDonald TT, Pallone F, Monteleone G. The aryl hydrocarbon receptor in inflammatory bowel disease: linking the environment to disease pathogenesis. Curr Opin Gastroenterol 2012;28(4):310-313
59. Zheng Y, Valdez PA, Danilenko DM, et al. Interleukin-22mediates early host defense against attaching and effacing bacterial pathogens. NatMed 2008;14(3):282-289.
60. Sugimoto K, Ogawa A, Mizoguchi E, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008;118(2):534-544.
61. Zenewicz LA, Yancopoulos GD, Valenzuela DM, et al. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008;29(6):947-957.
62. Trifari S, Kaplan CD, Tran EH, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct fromT(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009;10(8):864-871.
63. Monteleone I, Rizzo A, Sarra M, et al. Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology 2011;141(1): 237-248, 248.e1.
64. Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, formoderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebocontrolled trial. Gut 2012;61(12):1693- 1700.
65. Mannon PJ, Fuss IJ,Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351(20):2069-2079.
66. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;135(4):1130-1141.
67. Sandborn WJ,GasinkC,Gao LL, et al. Ustekinumab induction andmaintenance therapy in refractory Crohn's disease. N Engl JMed 2012;367(16):1519-1528.
68. McGeachy MJ, Bak-Jensen KS, Chen Y, et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007;8(12):1390-1397.
69. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314(5804):1461-1463.
70. Pidasheva S, Trifari S, Phillips A, et al. Functional studies on the IBDsusceptibility gene IL23R implicate reduced receptor function in the protective genetic variant R381Q. PLoSOne 2011;6(10):e25038.